Dr. Nelson Erlick has a wide range of experience in medical/surgical specialty practice and in analyzing some of the most controversial and complicated medical technologies of our time.
Dr. Nelson Erlick holds a Doctor of Podiatric Medicine (DPM) from the Pennsylvania College of Podiatric Medicine, a Master of Science (MS) in Biology from Drexel University, and a Bachelor of Arts (BA) in Biochemistry and Natural Science from the University of Pennsylvania. He completed a surgical residency at Oxford Hospital. He has twice won the top award in podiatry for original research (William Stickel Gold Medal) on topics in wound healing and diabetes, respectively, as well as the top research award for podiatric residents (O'Neal Jones and Feldman Award) for developing a new skeletal radiographic measurement technique.
Dr. Erlick was a Board Certified Podiatric Surgeon and was in private practice for eleven years. After retiring from private practice, Dr. Erlick served as the Senior Health Technology Analyst at ECRI, an internationally renowned medical technology "think tank." At ECRI, Dr. Erlick research, analyzed, and wrote many comprehensive, unbiased, precedent-setting assessments on a wide variety of high-profile, controversial topics including: high-dose chemotherapy with "bone marrow transplants" for the treatment of breast cancer, ovarian cancer, lung cancers, malignant melanoma, renal cell cancer, and multiple myeloma; and innovative developments in biotechnology, laser therapy, wound healing, and pain management. Agencies of the U.S. government, including the Health Care Finance Administration (Medicare), various state regulatory agencies, and major health insurers have used Dr. Erlick's medical technology assessment reports to determine whether medical innovations are safe and effective for the public.
After leaving ECRI, Dr. Erlick worked in the pharmaceutical industry, first as a Senior Clinical Writer, where he was responsible for interpreting and writing key clinical and statistical documents for submission to the Food and Drug Administration, then as a Manager of Medical Information and Technical Writing, where he participated in early drug development processes, including designing and writing clinical study protocols.
Currently, Dr. Erlick is Senior Strategist for the Strategic Scientific Services division of a large, international medical communications firm. He is the senior scientific source for matters involving pharmacoeconomic (decision) analysis, statistics, and meta-analysis.
Provided by the author, March 2003.